Advertisement
U.S. markets closed
  • S&P 500

    5,123.41
    -75.65 (-1.46%)
     
  • Dow 30

    37,983.24
    -475.84 (-1.24%)
     
  • Nasdaq

    16,175.09
    -267.10 (-1.62%)
     
  • Russell 2000

    2,003.17
    -39.43 (-1.93%)
     
  • Crude Oil

    85.45
    +0.43 (+0.51%)
     
  • Gold

    2,360.20
    -12.50 (-0.53%)
     
  • Silver

    27.97
    -0.28 (-0.99%)
     
  • EUR/USD

    1.0646
    -0.0085 (-0.79%)
     
  • 10-Yr Bond

    4.4990
    -0.0770 (-1.68%)
     
  • GBP/USD

    1.2451
    -0.0104 (-0.83%)
     
  • USD/JPY

    153.2400
    +0.0370 (+0.02%)
     
  • Bitcoin USD

    63,562.93
    -3,502.39 (-5.22%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,995.58
    +71.78 (+0.91%)
     
  • Nikkei 225

    39,523.55
    +80.92 (+0.21%)
     

Paragonix Technologies, Leader in Organ Transplantation, Opens New U.S. Headquarters

Grand Opening Marks a Milestone in Company’s Expansion and Innovation in Organ Transplantation

WALTHAM, Mass., October 04, 2023--(BUSINESS WIRE)--Paragonix Technologies, a pioneer in organ transplant solutions, is excited to announce the opening of its new corporate headquarters in Waltham, Massachusetts, marking a significant milestone in its journey to advance organ transplant innovations. This expansion reflects the company's continued growth and its enduring commitment to serving clinicians and patients worldwide. The facility is equipped with state-of-the-art research and development laboratories and collaborative spaces designed to foster innovation and teamwork across departments in the ever-evolving field of organ transplantation.

The expansive 34,000-square-foot center serves as a consolidated hub of Paragonix’s diverse operations, located in the vibrant technology corridor of Greater Boston. This pivotal move comes during a phase of accelerated growth for Paragonix, which has experienced remarkable development since its establishment in 2010. The facility’s capacity is designed to meet escalating customer demand and accommodate future expansion, with further plans to grow the Paragonix team.

"Witnessing the company’s evolution has been remarkable," said Dr. Lisa Anderson, CEO and co-founder of Paragonix Technologies. "Paragonix was conceived with a vision to revolutionize organ transplantation through accessible, clinically-proven, and cost-effective technologies, in close collaboration with the clinical community. Today, we are thrilled to inaugurate our first major U.S. headquarters, a significant step forward in continuing our pioneering research and development efforts in transplant products and services. The facility will act as a hub for all contributors to our mission, enabling us to redefine standards of care and offer unparalleled support to the organ transplant community."

This strategic move is on the heels of Paragonix’s announcement of FDA clearance for its innovative BAROguard Donor Lung Preservation System, representing the company’s fourth FDA cleared device. The new headquarters will also accommodate support teams essential for extending the company’s national clinical and surgical services and growing pipeline of next generation devices. With a presence in over 120 transplant centers worldwide and having safeguarded over 4,000 donor organs, Paragonix is a trusted name in transplant medicine.

"The new headquarters will enable us to cater efficiently to the growing needs of our business and escalating demands of our clients," said Garrett Riddle, Senior Vice President of Operations at Paragonix Technologies. "We are proud to facilitate this essential expansion, allowing Paragonix to develop innovative transplant solutions in a unified, dynamic environment."

For more information about Paragonix Technologies, please visit: https://www.paragonixtechnologies.com/.

About Paragonix Technologies

Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.

Paragonix Technologies provides Advanced Organ Preservation ("AOP") devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com.

Connect with us on LinkedIn: Paragonix Technologies
Follow us on Twitter: @ParagonixSherpa
Like Us on Facebook: Paragonix SherpaPak

L-527 Ver 0

View source version on businesswire.com: https://www.businesswire.com/news/home/20231004230768/en/

Contacts

Adam Lafreniere
Sr. Director, Marketing
marketing@paragonixtechnologies.com

Advertisement